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Background
Miniaturized extracorporeal circulation (MECC) has been
implemented in clinical practice for the last decade with
superior results regarding postoperative morbidity and
mortality mainly in coronary procedures. We challenged
this technique in high-risk patients with end-stage heart
failure undergoing left ventricular assist device (LVAD)
implantation.
Methods
Four patients with end-stage ischemic heart failure were
included in this study. All patients were inotrope depen-
dent (INTERMACS class 2) and their preoperative
evaluation considered them to be high-risk for develop-
ing postoperative right ventricular failure. Hence, opti-
mization of right ventricular function was performed
preoperatively following a protocol based on intermit-
tent administration of doses of levosimendan. Two Jar-
vik 2000 and two HeartWare LVADs were implanted on
beating heart using MECC system. Surgical strategy
included retrograde autologous priming of the circuit
and avoidance of administering cardioplegia.
Results
All procedures were uneventful and patients were
weaned-off MECC on the LVAD smoothly. There was
no need for nitric oxide administration either intrao-
peratively or in the ICU. No blood or blood product
was transfused intraoperatively while minimal blood
transfusion was required postoperatively. Renal and
hepatic laboratory parameters were maintained within
normal range. All patients were discharged from the
ICU in a median of 4 days without need for inotropic
support.
Conclusions
This is the first reported series on the use of MECC in
high-risk patients undergoing LVAD implantation. MECC
provides haemodynamic stability throughout the proce-
dure, while it minimizes haemodilution and preserves
right ventricular function, which is of utmost importance.
We believe that MECC use without ischemic time for the
myocardium should be the standard operative technique
for LVAD implantation, especially in high-risk patients.
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